HealthyPOROUS-preFXNCT06567054
Clinical Study to Predict the Risk of Bone Fractures With the POROUS Ultrasound Device
A study testing Measurements with the POROUS R3C ultrasound device at the midshaft tibia, DXA measurement of the hip and lumbar spine and DXA-based Vertebral Fracture Assessment (VFA) in people with Healthy and Osteopenia, run by POROUS GmbH at 6 sites in 3 countries.
Trial summary
Osteoporosis is a widespread medical condition among older people. It causes the bones to weaken and become more likely to break. Osteoporosis and bone fracture risk are currently evaluated by looking at clinical risk factors and measuring bone mineral density (BMD). Read more about this study
- Who is it for?
- Ages 56 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy, Osteopenia, Osteoporosis
- What is being tested?
- Measurements with the POROUS R3C ultrasound device at the midshaft tibia, DXA measurement of the hip and lumbar spine and DXA-based Vertebral Fracture Assessment (VFA)
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,600 participants
- Where
- 6 sitesin 3 countries
- Study dates
- 3 Mar 2025to Aug 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 56 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female or male individuals aged 56 to and including 85 years.
- Written informed consent has been obtained.
- Assessment of risk factors for hip and vertebral fractures:
- To avoid over- and under-recruiting with regard to the required sample size of participants with ≥ 2-fold increased age-and sex-adjusted risk for hip and vertebral fractures and participants with < 2-fold increased age- and sex-adjusted risk, clinical risk factors necessary for the calculation of the risk for hip and vertebral fractures (based on the risk calculation scheme outlined in the DVO osteoporosis guideline) are assessed at Screening.
- Vertebral fractures:
- Vertebral fracture(s) during the last year
Show all 48Show fewer
- Vertebral fracture(s) > 12 months ago
- Number of vertebral fractures
- Maximal severity of vertebral fractures, according to Genant
- Hip fractures and other fractures:
- Hip fracture during the last year
- Hip fracture > 12 months ago
- Humerus fracture
- Pelvic fracture
- Wrist (radius distal) fracture
- General risk factors:
- Mother or father with hip fracture, if the participant is under 75 years of age
- Significant alcohol consumption (50 g/day or more)
- Smoking (currently > 10 cigarettes/day)
- Chronic-obstructive pulmonary disease (COPD)
- Body Mass Index (BMI) ≤ 20
- Medication:
- Opioids
- Proton pump inhibitors > 3 months
- Oral glucocorticoids > 3 months (prednisone equivalent in mg/d)
- Fall-associated risk factors/geriatrics:
- Number of falls within the last year
- Chronic hyponatremia
- Depression/antidepressants
- Anticonvulsants in epilepsy
- Immobility (being dependent on a walking aid)
- Alzheimer's disease/dementia
- Parkinson's disease
- Multiple sclerosis
- Stroke
- Time up and Go Test > 12 seconds in participants ≥ 70 years of age
- Endocrinology:
- Diabetes mellitus Type I
- Diabetes mellitus Type II (including time since onset)
- Primary hyperparathyroidism
- Thyroid-stimulating hormone (TSH) suppression (if yes, including TSH level)
- Other diseases/medications:
- Chronic heart failure
- Monoclonal gammopathy of unclear significance (MGUS)
- Chronic kidney disease (CKD) stages 3a, 3b, 4
- Rheumatology:
- Rheumatoid arthritis
- Axial spondyloarthritis
Who cannot join
- Presence of diseases that rule out valid measurements with the DXA and/or POROUS R3C devices (e.g., fractures or metal implants in the examined bones, paralysis of the lower extremities, severe bone abnormalities).
- Inability to undergo the investigations required by the Clinical Investigation Plan (CIP) or cognitive limitations that preclude understanding of the Participant Information Sheet and the Informed Consent Document.
- Previous medical procedures involving exposure to a cumulative dose of ionising radiation deemed by the Investigator to exceed usual limits within standard of care.
- Pregnancy and breastfeeding
- Enrolment in any other interventional clinical study (current or during the last three months)
- Individual is in custody by order of an authority or a court of law.
Show all 20Show fewer
- Close affiliation with an investigational site, e.g. employed at investigational site, close relative of an investigator, dependent person (e.g. student of the investigational site).
- Further, individuals who are being or have been treated within the indicated period prior to the beginning of the study with any of the following antiresorptive therapies are excluded from the clinical investigation:
- Bisphosphonates (due to residual effects of bisphosphonates after discontinuation):
- Intravenous (IV) zoledronate within the last 3 years.
- Oral alendronate within the last year, if (continuous) treatment duration before was > 1 year.
- Oral risedronate within the last year, if (continuous) treatment duration before was > 1 year.
- Ibandronate (IV or oral) within the last year, if (continuous) treatment duration before was > 1 year.
- Denosumab within the last 3 years
- Hormone replacement therapy (HRT) including combination therapy or oestrogen alone in postmenopausal women within the last 6 months.
- Raloxifene within the last 6 months.
- Individuals who are being or have ever been treated with any of the following anabolic therapies are excluded from the clinical investigation:
- Teriparatide
- Romosozumab
- Abaloparatide.
Trial locations and contacts
6 sites in 3 countries.
6 sites in 3 countries
Germany4 sites
Department of Rheumatology, Charité Universitätsmedizin Berlin, Charite Campus Mitte
Berlin, State of Berlin, 10117
Centre of Muscle and Bone Research (ZMK), Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Berlin, State of Berlin, 12207
Department for Orthopedy, Trauma and Reconstructive Surgery, Section of Geriatric Traumatology, University Hospital Halle (Saale)
Halle, 06120
Department of Endocrinology, Reproductive Medicine and Osteology Clinic for Gynecology and Obstetrics, University Hospital of Giessen and Marburg
Marburg, 35043
Austria1 site
Division for Endocrinology and Metabolism, Department of Medicine 3, Medical University Vienna
Vienna, 1090
Netherlands1 site
VieCuri Medisch Centrum, Department of Internal Medicine, Venlo
Venlo, 5912 BI
About this study
Official title: A Prospective, Single-cohort, Multicentre Clinical Investigation to Evaluate the Performance of POROUS R3C Ultrasound Device for Fracture Risk Prediction in Middle-aged and Elderly Men and Women
Osteoporosis is a widespread medical condition among older people. It causes the bones to weaken and become more likely to break. Osteoporosis and bone fracture risk are currently evaluated by looking at clinical risk factors and measuring bone mineral density (BMD). The lower the BMD is, the higher the risk of osteoporotic fractures in the future. However, most bone fractures occur in people who do not have very low BMD values. This means that osteoporosis and fracture risk are often not diagnosed. Many of these non-diagnosed patients would benefit from treatment to reduce the probability of bone fractures.
An X-ray device called DXA is the main tool used to diagnose osteoporosis and fracture risk clinically. DXA measures two-dimensional BMD in the hip and spine. The POROUS ultrasound device measures various properties of the outer layer of the bone in the lower leg. It has several advantages over DXA: (1) its image resolution is higher and three-dimensional; (2) it can detect bone changes without radiation; (3) it can detect these bone changes early and how they change over time.
Read more
For this clinical study, we will recruit men and women over 55 years old. Most will have clinical risk factors, such as background diseases, for developing osteoporosis. The study is anticipated to last 4 years.
Our major research questions are:
- Can the POROUS ultrasound device predict fracture risk?
- How does its performance compare to DXA?
- What is the safety of the new device?
The participants will:
- answer questions about their medical history.
- be measured for height and weight, and take a physical test.
- be examined for the presence of 'silent' fractures in the spine.
- be examined at the beginning and end of the study with the two devices, DXA and POROUS.
- be called by telephone every six months and asked if they suffer from new bone fractures, take any medication that might affect their bones, or if their health status has changed.
The participants will be monitored for 3 years.
Read the detailed description
Background and purpose:
Currently, osteoporosis and fracture risk are indirectly evaluated via the assessment of risk factors and bone mineral density (BMD) measurement. Although BMD is currently the most important indicator for osteoporosis-associated bone fractures, most of those fractures occur in persons who do not show pathologically reduced BMD value. Therefore, osteoporosis is one of the most frequently underdiagnosed common diseases. Established guidelines for the diagnosis of osteoporosis recommend the assessment of fracture risk factors and the T-Score, which is derived from the measurement of areal bone mineral density (aBMD) by means of DXA at major fracture sites, i.e., spine and proximal femur. DXA is regarded as the "gold standard" well-established methodology to determine aBMD for diagnostic purposes. Epidemiological data emphasize the urgency of developing diagnostic tools that can improve fracture risk prediction so that patients can be treated with the appropriate anti-osteoporotic therapies. Current guidelines for diagnosis and treatment lead to treatment gaps. It is estimated that at least 80% of males and 77% of females who would benefit from osteoporosis treatment are neither diagnosed nor treated in Germany.
Device description:
The POROUS R3C ultrasound device enables a non-invasive, non-ionizing quantitative detection of microstructural bone changes. As opposed to diagnosis based on a combination of clinical risk factors and a relative decrease of BMD, the novel device enables detecting pathological changes of bone microstructure at an earlier timepoint as well as monitoring such changes in a longitudinal manner. In the course of this clinical investigation, data will be collected to establish relevant ultrasound-based physical biomarkers for the prediction of fracture risk.
Study design:
This is a single-cohort, multicenter, prospective, age- and sex-stratified study in participants > 55 years of age. In this study, Baseline data will be collected to establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device and test its performance in predicting fracture risk. Further, the performance of the POROUS R3C ultrasound device in the analysis of cortical bone properties and discrimination of prevalent fractures will be assessed. Participants will be enrolled into different groups based on their age (consisting of five-year bands), sex (males and females), and risk status for hip and vertebral fractures (i.e., high risk of ≥ 2-fold and low risk of < 2-fold increased risk compared to the general population of the same age and sex).
Two measurements with each device: investigational device (POROUS R3C ultrasound device at the midshaft tibia), and comparator (DXA of the lumbar spine and proximal femur), are scheduled per participant:
- Measurement 1: At Baseline
- Measurement 2: At the End-of-Study (EoS) visit.
Study Part 1:
In Part 1, information on prevalent fractures will be used to establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device. In other words, Part 1 aims to establish the discriminative performance and a standardized gradient of fracture risk based on prevalent fractures. In addition, the discriminative performance of the POROUS R3C ultrasound device and standard-of-care DXA will be compared based on prevalent fractures.
Study Part 2:
In Part 2, information on incident fractures will be used to establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device. It will be developed to demonstrate the predictive performance of the derived fracture risk. In other words, Part 2 aims to establish a standardized gradient of fracture risk based on incident fractures. In addition, the predictive performance of the POROUS R3C ultrasound device and standard-of-care DXA will be compared based on incident fractures.
The collection of data obtained by DXA and the POROUS R3C device at the EoS visit is used to monitor changes in the bone state in comparison to the respective data obtained at Baseline. However, only measurement data obtained by the POROUS R3C device at Baseline is used to develop the POROUS-Score model and the standardized gradient of fracture risk (for Part 1 and Part 2).
Primary objectives:
- Part 1 -To establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device based on prevalent fractures.
- Part 2 - To establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device based on incident fractures and to demonstrate the predictive performance of the derived fracture risk.
Secondary objectives:
- Part 1 - To compare the discriminative performance of the POROUS R3C ultrasound device and standard-of-care DXA based on prevalent fractures.
- Part 2 - To assess the safety of the POROUS R3C ultrasound device by monitoring adverse events affecting participants or the healthcare professionals using the device.
- Part 2 - To compare the predictive performance of the POROUS R3C ultrasound device and standard-of-care DXA based on incident fractures.
Exploratory objectives:
- Part 1 - To assess the association of various ultrasound parameters measured by the POROUS R3C ultrasound device with specific clinical risk factors/indicators for vertebral and hip fractures (as outlined by the DVO) and prevalent fractures.
- Part 1 - To demonstrate the discriminative performance of the POROUS R3C ultrasound device based on subgroups of prevalent fractures, e.g., hip, vertebral, and major osteoporotic fractures.
- Part 1 - To establish reference data for developing age-adjusted POROUS Z-scores using the POROUS R3C ultrasound device based on prevalent fractures.
- Part 2 - To assess the association of various ultrasound parameters measured by the POROUS R3C ultrasound device with specific clinical risk factors/indicators for vertebral and hip fractures (as outlined by the DVO) and incident fractures.
- Part 2 - To demonstrate the predictive performance of the POROUS R3C ultrasound device based on subgroups of incident fractures, e.g., hip, vertebral, and major osteoporotic fractures.
- Part 2 - To establish reference data for developing age-adjusted POROUS Z-scores using the POROUS R3C ultrasound device based on incident fractures.
- Part 2 - To explore the treatment effect of anti-osteoporotic medication
- Part 2 - To explore the treatment effect of drugs known to influence bone metabolism.
Participants:
A total of 1,600 female and male participants (> 55 years of age) will be included in the investigation. This population is planned to include 1,120 participants with ≥ 2-fold increased age- and sex-adjusted risk for hip and vertebral fractures and 480 participants with a < 2-fold increased age- and sex-adjusted risk for hip and vertebral fractures.
Stratification of participants, fracture risk < 2-fold increased risk:
- Age group 56-60, males/females = 40 per group, total = 80.
- Age group 61-65, males/females = 40 per group, total = 80.
- Age group 66-70, males/females = 40 per group, total = 80.
- Age group 71-75, males/females = 40 per group, total = 80.
- Age group 76-80, males/females = 40 per group, total = 80.
- Age group 81-85, males/females = 40 per group, total = 80.
Stratification of participants, fracture risk ≥ 2-fold increased risk:
- Age group 66-70, females = 100 per group.
- Age group 71-75, males = 100 per group, females = 160 per group, total = 260.
- Age group 76-80, males/females = 180 per group, total = 360.
- Age group 81-85, males/females = 200 per group, total = 400.
The expected number of incident fractures* ~140 (at 24 months), ~210 (at 36 months).
*The assumed number of fractures per analysis group (DXA and POROUS R3C) at Month 24 and Month 36, respectively, is based on age- and sex-matched incidence rates for fractures (Rupp et al., Deutsches Ärzteblatt International, 2021), further updated by data on the incidence of vertebral fractures (Fink et al., JBMR, 2005).
Risk calculation for hip and vertebral fractures:
At Screening, assessment of clinical risk factors and application of risk calculating scheme as outlined in the Dachverband Osteologie (DVO, tri-national umbrella association of German, Austrian, and Swiss medical and scientific professional societies in the field of bone diseases) osteoporosis guideline will determine whether a participant is at increased risk (≥ 2-fold compared to the general population of the same age and sex) for hip and vertebral fractures. Please note that the calculation of the pertinent risk as performed in this study does not include any DXA-based BMD measurements and T-Scores. No DXA BMD measurement or DXA-based vertebral fracture assessment (VFA) will be conducted at Screening. Noteworthy, DXA-based BMD measurement results and T-Scores will be included in the different analyses of the study endpoints but not for the risk calculation at Screening as described above. Screened and eligible individuals will be enrolled in the investigation until the necessary sample size for his/her corresponding group (based on age, sex, and risk status) has been reached (see Table below). To avoid over-recruiting, once the necessary sample size for one group has been reached, no further individuals with matching age band, sex, and risk status will be enrolled in the study.
Duration of the study:
The planned overall clinical investigation is expected to take 48 months, including an enrolment period of approximately 12 months and a clinical investigation period of 36 months. Per participant, the total time of participation in the investigation will take 36 months. 20 months (+/-1 month) after the first participant has been included in the investigation, a checkpoint assessment of the number of fracture events so far recorded is planned. The aim is to assess whether the number of fractures projected to be reached after each participant will have been followed-up for 24 months would be sufficient for a test of the primary endpoint with sufficient statistical power. If this is the case, the clinical investigation period will be shortened to 24 months (correspondingly, the overall duration will be shortened to 36 months). If, at the checkpoint assessment, the number of fractures is insufficient, the follow-up period will remain as planned and the EoS visit will take place at 36 months, amounting to the originally planned overall duration of 48 months.
Duration of participation:
The total time of participation in the investigation will take 36 months per participant, with the option to be shortened to an investigational period of 24 months based on the results of a checkpoint assessment of reported fractures scheduled at Month 20 (+/-1 month).
Fracture risk prediction model:
The diagnostic value of physical biomarkers, which are derived from Baseline measurements with the POROUS R3C ultrasound device, will be assessed, and selected physical biomarkers will be integrated into a model, resulting in a composite POROUS-Score, for fracture risk prediction. In Part 1, the model will be developed using data on prevalent fractures, while in Part 2, the model will be developed using data on incident fractures. The resulting POROUS-Scores are, therefore, different in Part 1 and Part 2. In Part 1, it is termed POROUS-Score(Prev), whereas in Part 2, it is termed POROUS-Score. Additionally, anthropometric data (age, sex, and BMI) will be evaluated and selected for adding predictive strength to the prediction model.
Part 1:
Prevalent fractures will be recorded, and all relevant variables, including ultrasound parameter values and anthropometric information, will be used to perform partial least squares - discriminant analysis (PLS-DA) followed by subwindow permutation analysis using a Monte-Carlo approach. Only variables that have statistically significant discriminative power will be used in the next step, where a new fracture discrimination model will be created using PLS-DA analysis. Thereafter, the performance of the model will be investigated using receiver operating characteristics (ROC) analysis. More precisely, logistic discriminant analysis will be performed. Area under the curve (AUC) values and their confidence intervals will be computed from ROC curves for each model. Internal validation of the model will be performed by using cross-validation followed by bootstrap analysis. Odds ratios will be determined for both the final composite POROUS-Score(Prev) (generated from the internally validated model) and DXA T-Score. Standardized odds ratios (sOR) will be calculated, i.e., the fold-increase of the relative fracture risk per standard deviation decrease of the respective score. The discriminative ability of the POROUS model for prevalent fractures is demonstrated if the lower limit of the 90% confidence interval of the corrected sOR is higher than 1.
Part 2:
Incident fractures will be recorded, and all relevant variables, including ultrasound parameter values and anthropometric information, will be used to perform PLSDA followed by sub-window permutation analysis using a Monte-Carlo approach. Only variables that have statistically significant predictive power will be used in the next step, where a multivariate Cox-proportional Hazard model will be performed to calculate the hazard ratio (HR). Then, the model performance will be investigated using ROC analysis. Internal validation of the model will be done by running cross-validation followed by Bootstrap analysis. The standardized relative risk (sRR) will be calculated, i.e., the fold-increase of the relative fracture risk per standard deviation decrease of the respective score. The sRR will be determined for both the final composite POROUS-Score (generated from the internally validated model) and DXA T-Score. The predictive ability of the POROUS model for incident fractures is demonstrated if the lower limit of the 90% confidence interval of the corrected sRR is higher than 1.
Clinical procedures:
The following clinical procedures are performed during the investigation:
Screening
- Informed consent
- Inclusion/exclusion criteria
- Calculation of individual risk for hip and vertebral fractures as per modified version of the DVO risk calculation scheme (excluding DXA-based BMD measurement and T-Score)
- Enrolment into corresponding age-sex-risk group.
Baseline (Visit 2, 0-14 days after Screening)
- Scanning with the POROUS R3C ultrasound device at the central anteromedial tibia region
- Scanning with DXA (aBMD of the lumbar spine and proximal femur).
- Fracture anamnesis, including DXA-based VFA. Alternatively, VFA may be replaced by projectional radiography if VFA is not available.
- Assessment of clinical risk indicators (as per DVO guideline)
- Assessment of concomitant medication (initiation of anti-osteoporotic medication as well as oral glucocorticoids, proton pump inhibitors, aromatase inhibitors, hormone ablation therapy/antiandrogens in males).
- Recording of adverse events.
Follow-up period Interim visits (phone survey) - Visits 3-7 at Month 6, 12, 18, 24, 30 ± 14 days
- Assessment of incident fractures (to be validated by requesting medical documents - X-ray images, physician's findings)
- Concomitant medication assessment
- Recording of adverse events
Early-termination (ET) visit/phone survey Participants who withdraw early (i.e., before undergoing the EoS visit) will be offered an ET clinical visit, including
- VFA (or projectional radiography of the spine, respectively, if VFA is not available)
- Anamnesis of incident fractures since the last visit/phone survey
- Concomitant medication assessment (see above)
- Recording of adverse events. (Alternatively, the visit can be conducted as a phone survey if the time gap since the last DXA/VFA is < 6 months or the participant is not available for a clinical visit).
EoS visit - Visit 8 at Month 36 ± 14 days
- Scanning with the POROUS R3C ultrasound device at the central anteromedial tibia region
- Scanning with DXA (aBMD of the lumbar spine and proximal femur).
- Assessment of incident fractures including VFA (or projectional radiography of the spine)
- Re-assessment of fracture risk factors/indicators as per DVO guideline and recalculation of risk for hip and vertebral fractures
- Concomitant medication assessment
- Recording of adverse events.
Subgroup analysis:
General subgroups for analyses are defined based on age, sex, and risk (for hip and vertebral fractures). Stratification groups are presented in the table on "Number of participants to be included in the investigation" included above. In addition, subgroup analyses are done to monitor treatment effects, as described in the exploratory endpoint of Part 2.
- Conditions
- Healthy, Osteopenia, Osteoporosis
- Being tested
- Measurements with the POROUS R3C ultrasound device at the midshaft tibia, DXA measurement of the hip and lumbar spine, DXA-based Vertebral Fracture Assessment (VFA), Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)
- Keywords
- Osteoporosis, Osteopenia, Bone Tissue, Diagnostic Imaging, Ultrasound, Ultrasonography, Ultrasonic Diagnosis, DEXA Scan, DXA Scan, Dual X-Ray Absorptiometry, Bone Fractures, Osteoporotic Fractures, Hip Fractures, Spinal Fractures, Low Bone Mineral Density
- Medical subject headings
- Bone Diseases, Metabolic, Osteoporosis, Fractures, Bone, Osteoporotic Fractures, Hip Fractures, Spinal Fractures
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Measurements with the POROUS R3C ultrasound device at the midshaft tibiaDevice
The POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria.
DXA measurement of the hip and lumbar spineDevice
The following DXA measurements are to be performed:
- Spine L1-4
- Hip left
- Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan.
DXA-based Vertebral Fracture Assessment (VFA)Device
DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5.
Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)Device
Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5.
| Study group | Role | What they receive |
|---|---|---|
| Fracture risk prediction in middle-aged and elderly men and women | Experimental | All participants are examined with the investigational device (POROUS R3C ultrasound device) and a comparator device (DXA). Receives: Device: Measurements with the POROUS R3C ultrasound device at the midshaft tibia; Device: DXA measurement of the hip and lumbar spine; Device: DXA-based Vertebral Fracture Assessment (VFA); Device: Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical Endpoint, Part 1 - POROUS-Score based on prevalent fractures
Prevalent fractures are the focus of the analysis in Part 1, i.e., fractures that occurred prior to the Baseline visit. This is reflected in establishing corrected standardized odds ratio (sOR) for the POROUS R3C ultrasound device-derived POROUS-Score. Statistically significant discriminative power of the sOR will be achieved if the lower limit of the 90% confidence interval of the sOR is greater than 1. The POROUS-Score will be evaluated to demonstrate the discriminative performance of the POROUS R3C ultrasound device for prevalent fractures.
Outcome measure: POROUS-Score (units on scale)
Measured: 12 months
Clinical Endpoint, Part 2 - POROUS-Score based on incident fractures
Incident fractures are the focus of the analysis in Part 2, i.e., fractures that occur after the Baseline visit until the EoS. This is reflected in establishing corrected standardized relative risk (sRR) for the POROUS R3C ultrasound device-derived POROUS-Score. Statistically significant prediction power of the sRR will be achieved if the lower limit of the 90% confidence interval of the sRR is greater than 1. The POROUS-Score will be evaluated to demonstrate the predictive performance of the POROUS R3C ultrasound device for incident fractures. Fractures, which are associated with cortical bone and/or increasing age, will be considered for collecting information on both prevalent and incident fractures. Any incident fractures caused by high-energy external forces will be excluded (censored) from the analysis.
Outcome measure: POROUS-Score (units on scale)
Measured: 24 or 36 months
Secondary outcomes (5)
Safety Endpoint
In order to establish that the POROUS R3C ultrasound device is safe with a minimal number of adverse events affecting the participants or the healthcare professionals using the device, the following safety endpoints are investigated:
- Incidence of procedural/device-related adverse events caused by the
- Absorbed energy
- Probe/transducer heating
- Irritation by ultrasound gel
- Release of substances
- Inappropriate hygiene measures.
- Other (serious) adverse events.
Measured: 36 or 48 months
Performance Endpoint, Part 1 - DXA T-score
Outcome measure: DXA T-score (units on scale)
Measured: Immediately after the intervention
Performance Endpoint, Part 1 - discriminative performance based on prevalent fractures
Establish discriminative performance of the POROUS R3C ultrasound device in comparison with DXA based on prevalent fractures. sOR values for both POROUS-Score and DXA T-Score will be compared by applying ROC analysis.
Outcome measure: POROUS-Score (units on scale)
Measured: 12 months
Performance Endpoint, Part 2 - DXA T-score
Outcome measure: DXA T-score (units on scale)
Measured: Immediately after the intervention
Performance Endpoint, Part 2 - predictive performance based on incident fractures
Establish predictive performance of the POROUS R3C ultrasound device in comparison with DXA based on incident fractures. Standardized hazard ratio (sHR) values for both POROUS-Score and DXA T-Score will be compared by applying Cox-proportional hazard modelling.
Outcome measure: POROUS-Score (units on scale)
Measured: 24 or 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2024
- Study start3 Mar 2025
- Primary completionMay 2029 (estimated)
- Study completionAug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Comparative, single-cohort, interventional study model: investigational device vs. comparator device. Measurements are performed on the same cohort of participants: Part 1 - cross-sectional study; Part 2 - prospective study.
- Masking
- None (open label)
- Enrolment
- 1,600 participants (actual)
Sponsor and investigators
- Lead sponsor
- POROUS GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- European Commission
- Responsible party
- Sponsor
- Investigators
- Gabriele G Armbrecht, MD, PhD, Principal investigator, Zentrum für Muskel- und Knochenforschung
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06567054
- Sponsor's protocol ID
- R3C-FX-02
- Other IDs
- CIV-24-04-046776, 190115994
- Acronym
- POROUS-preFX
- Status last verified
- Jun 2026
- First submitted
- 28 Jun 2024
- Last updated
- 5 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Armbrecht G, Nguyen Minh H, Massmann J, Raum K. Pore-Size Distribution and Frequency-Dependent Attenuation in Human Cortical Tibia Bone Discriminate Fragility Fractures in Postmenopausal Women With Low Bone Mineral Density. JBMR Plus. 2021 Sep 2;5(11):e10536. doi: 10.1002/jbm4.10536. eCollection 2021 Nov.
PubMed 34761144
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Single-cohort, Multicentre Clinical Investigation to Evaluate the Performance of POROUS R3C Ultrasound Device for Fracture Risk Prediction in Middle-aged and Elderly Men and Women
- ClinicalTrials.gov ID
- NCT06567054
- Acronym / sponsor ID
- POROUS-preFX / R3C-FX-02
- Conditions
- Healthy, Osteopenia, Osteoporosis
- Keywords
- Osteoporosis, Osteopenia, Bone Tissue, Diagnostic Imaging, Ultrasound, Ultrasonography, Ultrasonic Diagnosis, DEXA Scan
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,600 participants (actual)
- Lead sponsor
- POROUS GmbHIndustry (pharma, biotech, devices)
- Collaborators
- European Commission
- Study start
- 3 Mar 2025 (actual)
- Primary completion
- May 2029 (estimated)
- Study completion
- Aug 2029 (estimated)
- First posted
- 22 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Osteoporosis is a widespread medical condition among older people. It causes the bones to weaken and become more likely to break. Osteoporosis and bone fracture risk are currently evaluated by looking at clinical risk factors and measuring bone mineral density (BMD). The lower the BMD is, the higher the risk of osteoporotic fractures in the future. However, most bone fractures occur in people who do not have very low BMD values. This means that osteoporosis and fracture risk are often not diagnosed. Many of these non-diagnosed patients would benefit from treatment to reduce the probability of bone fractures.
An X-ray device called DXA is the main tool used to diagnose osteoporosis and fracture risk clinically. DXA measures two-dimensional BMD in the hip and spine. The POROUS ultrasound device measures various properties of the outer layer of the bone in the lower leg. It has several advantages over DXA: (1) its image resolution is higher and three-dimensional; (2) it can detect bone changes without radiation; (3) it can detect these bone changes early and how they change over time.
For this clinical study, we will recruit men and women over 55 years old. Most will have clinical risk factors, such as background diseases, for developing osteoporosis. The study is anticipated to last 4 years.
Our major research questions are:
- Can the POROUS ultrasound device predict fracture risk?
- How does its performance compare to DXA?
- What is the safety of the new device?
The participants will:
- answer questions about their medical history.
- be measured for height and weight, and take a physical test.
- be examined for the presence of 'silent' fractures in the spine.
- be examined at the beginning and end of the study with the two devices, DXA and POROUS.
- be called by telephone every six months and asked if they suffer from new bone fractures, take any medication that might affect their bones, or if their health status has changed.
The participants will be monitored for 3 years.
Detailed description
Background and purpose:
Currently, osteoporosis and fracture risk are indirectly evaluated via the assessment of risk factors and bone mineral density (BMD) measurement. Although BMD is currently the most important indicator for osteoporosis-associated bone fractures, most of those fractures occur in persons who do not show pathologically reduced BMD value. Therefore, osteoporosis is one of the most frequently underdiagnosed common diseases. Established guidelines for the diagnosis of osteoporosis recommend the assessment of fracture risk factors and the T-Score, which is derived from the measurement of areal bone mineral density (aBMD) by means of DXA at major fracture sites, i.e., spine and proximal femur. DXA is regarded as the "gold standard" well-established methodology to determine aBMD for diagnostic purposes. Epidemiological data emphasize the urgency of developing diagnostic tools that can improve fracture risk prediction so that patients can be treated with the appropriate anti-osteoporotic therapies. Current guidelines for diagnosis and treatment lead to treatment gaps. It is estimated that at least 80% of males and 77% of females who would benefit from osteoporosis treatment are neither diagnosed nor treated in Germany.
Device description:
The POROUS R3C ultrasound device enables a non-invasive, non-ionizing quantitative detection of microstructural bone changes. As opposed to diagnosis based on a combination of clinical risk factors and a relative decrease of BMD, the novel device enables detecting pathological changes of bone microstructure at an earlier timepoint as well as monitoring such changes in a longitudinal manner. In the course of this clinical investigation, data will be collected to establish relevant ultrasound-based physical biomarkers for the prediction of fracture risk.
Study design:
This is a single-cohort, multicenter, prospective, age- and sex-stratified study in participants > 55 years of age. In this study, Baseline data will be collected to establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device and test its performance in predicting fracture risk. Further, the performance of the POROUS R3C ultrasound device in the analysis of cortical bone properties and discrimination of prevalent fractures will be assessed. Participants will be enrolled into different groups based on their age (consisting of five-year bands), sex (males and females), and risk status for hip and vertebral fractures (i.e., high risk of ≥ 2-fold and low risk of < 2-fold increased risk compared to the general population of the same age and sex).
Two measurements with each device: investigational device (POROUS R3C ultrasound device at the midshaft tibia), and comparator (DXA of the lumbar spine and proximal femur), are scheduled per participant:
- Measurement 1: At Baseline
- Measurement 2: At the End-of-Study (EoS) visit.
Study Part 1:
In Part 1, information on prevalent fractures will be used to establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device. In other words, Part 1 aims to establish the discriminative performance and a standardized gradient of fracture risk based on prevalent fractures. In addition, the discriminative performance of the POROUS R3C ultrasound device and standard-of-care DXA will be compared based on prevalent fractures.
Study Part 2:
In Part 2, information on incident fractures will be used to establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device. It will be developed to demonstrate the predictive performance of the derived fracture risk. In other words, Part 2 aims to establish a standardized gradient of fracture risk based on incident fractures. In addition, the predictive performance of the POROUS R3C ultrasound device and standard-of-care DXA will be compared based on incident fractures.
The collection of data obtained by DXA and the POROUS R3C device at the EoS visit is used to monitor changes in the bone state in comparison to the respective data obtained at Baseline. However, only measurement data obtained by the POROUS R3C device at Baseline is used to develop the POROUS-Score model and the standardized gradient of fracture risk (for Part 1 and Part 2).
Primary objectives:
- Part 1 -To establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device based on prevalent fractures.
- Part 2 - To establish a corrected standardized gradient of fracture risk using the POROUS R3C ultrasound device based on incident fractures and to demonstrate the predictive performance of the derived fracture risk.
Secondary objectives:
- Part 1 - To compare the discriminative performance of the POROUS R3C ultrasound device and standard-of-care DXA based on prevalent fractures.
- Part 2 - To assess the safety of the POROUS R3C ultrasound device by monitoring adverse events affecting participants or the healthcare professionals using the device.
- Part 2 - To compare the predictive performance of the POROUS R3C ultrasound device and standard-of-care DXA based on incident fractures.
Exploratory objectives:
- Part 1 - To assess the association of various ultrasound parameters measured by the POROUS R3C ultrasound device with specific clinical risk factors/indicators for vertebral and hip fractures (as outlined by the DVO) and prevalent fractures.
- Part 1 - To demonstrate the discriminative performance of the POROUS R3C ultrasound device based on subgroups of prevalent fractures, e.g., hip, vertebral, and major osteoporotic fractures.
- Part 1 - To establish reference data for developing age-adjusted POROUS Z-scores using the POROUS R3C ultrasound device based on prevalent fractures.
- Part 2 - To assess the association of various ultrasound parameters measured by the POROUS R3C ultrasound device with specific clinical risk factors/indicators for vertebral and hip fractures (as outlined by the DVO) and incident fractures.
- Part 2 - To demonstrate the predictive performance of the POROUS R3C ultrasound device based on subgroups of incident fractures, e.g., hip, vertebral, and major osteoporotic fractures.
- Part 2 - To establish reference data for developing age-adjusted POROUS Z-scores using the POROUS R3C ultrasound device based on incident fractures.
- Part 2 - To explore the treatment effect of anti-osteoporotic medication
- Part 2 - To explore the treatment effect of drugs known to influence bone metabolism.
Participants:
A total of 1,600 female and male participants (> 55 years of age) will be included in the investigation. This population is planned to include 1,120 participants with ≥ 2-fold increased age- and sex-adjusted risk for hip and vertebral fractures and 480 participants with a < 2-fold increased age- and sex-adjusted risk for hip and vertebral fractures.
Stratification of participants, fracture risk < 2-fold increased risk:
- Age group 56-60, males/females = 40 per group, total = 80.
- Age group 61-65, males/females = 40 per group, total = 80.
- Age group 66-70, males/females = 40 per group, total = 80.
- Age group 71-75, males/females = 40 per group, total = 80.
- Age group 76-80, males/females = 40 per group, total = 80.
- Age group 81-85, males/females = 40 per group, total = 80.
Stratification of participants, fracture risk ≥ 2-fold increased risk:
- Age group 66-70, females = 100 per group.
- Age group 71-75, males = 100 per group, females = 160 per group, total = 260.
- Age group 76-80, males/females = 180 per group, total = 360.
- Age group 81-85, males/females = 200 per group, total = 400.
The expected number of incident fractures* ~140 (at 24 months), ~210 (at 36 months).
*The assumed number of fractures per analysis group (DXA and POROUS R3C) at Month 24 and Month 36, respectively, is based on age- and sex-matched incidence rates for fractures (Rupp et al., Deutsches Ärzteblatt International, 2021), further updated by data on the incidence of vertebral fractures (Fink et al., JBMR, 2005).
Risk calculation for hip and vertebral fractures:
At Screening, assessment of clinical risk factors and application of risk calculating scheme as outlined in the Dachverband Osteologie (DVO, tri-national umbrella association of German, Austrian, and Swiss medical and scientific professional societies in the field of bone diseases) osteoporosis guideline will determine whether a participant is at increased risk (≥ 2-fold compared to the general population of the same age and sex) for hip and vertebral fractures. Please note that the calculation of the pertinent risk as performed in this study does not include any DXA-based BMD measurements and T-Scores. No DXA BMD measurement or DXA-based vertebral fracture assessment (VFA) will be conducted at Screening. Noteworthy, DXA-based BMD measurement results and T-Scores will be included in the different analyses of the study endpoints but not for the risk calculation at Screening as described above. Screened and eligible individuals will be enrolled in the investigation until the necessary sample size for his/her corresponding group (based on age, sex, and risk status) has been reached (see Table below). To avoid over-recruiting, once the necessary sample size for one group has been reached, no further individuals with matching age band, sex, and risk status will be enrolled in the study.
Duration of the study:
The planned overall clinical investigation is expected to take 48 months, including an enrolment period of approximately 12 months and a clinical investigation period of 36 months. Per participant, the total time of participation in the investigation will take 36 months. 20 months (+/-1 month) after the first participant has been included in the investigation, a checkpoint assessment of the number of fracture events so far recorded is planned. The aim is to assess whether the number of fractures projected to be reached after each participant will have been followed-up for 24 months would be sufficient for a test of the primary endpoint with sufficient statistical power. If this is the case, the clinical investigation period will be shortened to 24 months (correspondingly, the overall duration will be shortened to 36 months). If, at the checkpoint assessment, the number of fractures is insufficient, the follow-up period will remain as planned and the EoS visit will take place at 36 months, amounting to the originally planned overall duration of 48 months.
Duration of participation:
The total time of participation in the investigation will take 36 months per participant, with the option to be shortened to an investigational period of 24 months based on the results of a checkpoint assessment of reported fractures scheduled at Month 20 (+/-1 month).
Fracture risk prediction model:
The diagnostic value of physical biomarkers, which are derived from Baseline measurements with the POROUS R3C ultrasound device, will be assessed, and selected physical biomarkers will be integrated into a model, resulting in a composite POROUS-Score, for fracture risk prediction. In Part 1, the model will be developed using data on prevalent fractures, while in Part 2, the model will be developed using data on incident fractures. The resulting POROUS-Scores are, therefore, different in Part 1 and Part 2. In Part 1, it is termed POROUS-Score(Prev), whereas in Part 2, it is termed POROUS-Score. Additionally, anthropometric data (age, sex, and BMI) will be evaluated and selected for adding predictive strength to the prediction model.
Part 1:
Prevalent fractures will be recorded, and all relevant variables, including ultrasound parameter values and anthropometric information, will be used to perform partial least squares - discriminant analysis (PLS-DA) followed by subwindow permutation analysis using a Monte-Carlo approach. Only variables that have statistically significant discriminative power will be used in the next step, where a new fracture discrimination model will be created using PLS-DA analysis. Thereafter, the performance of the model will be investigated using receiver operating characteristics (ROC) analysis. More precisely, logistic discriminant analysis will be performed. Area under the curve (AUC) values and their confidence intervals will be computed from ROC curves for each model. Internal validation of the model will be performed by using cross-validation followed by bootstrap analysis. Odds ratios will be determined for both the final composite POROUS-Score(Prev) (generated from the internally validated model) and DXA T-Score. Standardized odds ratios (sOR) will be calculated, i.e., the fold-increase of the relative fracture risk per standard deviation decrease of the respective score. The discriminative ability of the POROUS model for prevalent fractures is demonstrated if the lower limit of the 90% confidence interval of the corrected sOR is higher than 1.
Part 2:
Incident fractures will be recorded, and all relevant variables, including ultrasound parameter values and anthropometric information, will be used to perform PLSDA followed by sub-window permutation analysis using a Monte-Carlo approach. Only variables that have statistically significant predictive power will be used in the next step, where a multivariate Cox-proportional Hazard model will be performed to calculate the hazard ratio (HR). Then, the model performance will be investigated using ROC analysis. Internal validation of the model will be done by running cross-validation followed by Bootstrap analysis. The standardized relative risk (sRR) will be calculated, i.e., the fold-increase of the relative fracture risk per standard deviation decrease of the respective score. The sRR will be determined for both the final composite POROUS-Score (generated from the internally validated model) and DXA T-Score. The predictive ability of the POROUS model for incident fractures is demonstrated if the lower limit of the 90% confidence interval of the corrected sRR is higher than 1.
Clinical procedures:
The following clinical procedures are performed during the investigation:
Screening
- Informed consent
- Inclusion/exclusion criteria
- Calculation of individual risk for hip and vertebral fractures as per modified version of the DVO risk calculation scheme (excluding DXA-based BMD measurement and T-Score)
- Enrolment into corresponding age-sex-risk group.
Baseline (Visit 2, 0-14 days after Screening)
- Scanning with the POROUS R3C ultrasound device at the central anteromedial tibia region
- Scanning with DXA (aBMD of the lumbar spine and proximal femur).
- Fracture anamnesis, including DXA-based VFA. Alternatively, VFA may be replaced by projectional radiography if VFA is not available.
- Assessment of clinical risk indicators (as per DVO guideline)
- Assessment of concomitant medication (initiation of anti-osteoporotic medication as well as oral glucocorticoids, proton pump inhibitors, aromatase inhibitors, hormone ablation therapy/antiandrogens in males).
- Recording of adverse events.
Follow-up period Interim visits (phone survey) - Visits 3-7 at Month 6, 12, 18, 24, 30 ± 14 days
- Assessment of incident fractures (to be validated by requesting medical documents - X-ray images, physician's findings)
- Concomitant medication assessment
- Recording of adverse events
Early-termination (ET) visit/phone survey Participants who withdraw early (i.e., before undergoing the EoS visit) will be offered an ET clinical visit, including
- VFA (or projectional radiography of the spine, respectively, if VFA is not available)
- Anamnesis of incident fractures since the last visit/phone survey
- Concomitant medication assessment (see above)
- Recording of adverse events. (Alternatively, the visit can be conducted as a phone survey if the time gap since the last DXA/VFA is < 6 months or the participant is not available for a clinical visit).
EoS visit - Visit 8 at Month 36 ± 14 days
- Scanning with the POROUS R3C ultrasound device at the central anteromedial tibia region
- Scanning with DXA (aBMD of the lumbar spine and proximal femur).
- Assessment of incident fractures including VFA (or projectional radiography of the spine)
- Re-assessment of fracture risk factors/indicators as per DVO guideline and recalculation of risk for hip and vertebral fractures
- Concomitant medication assessment
- Recording of adverse events.
Subgroup analysis:
General subgroups for analyses are defined based on age, sex, and risk (for hip and vertebral fractures). Stratification groups are presented in the table on "Number of participants to be included in the investigation" included above. In addition, subgroup analyses are done to monitor treatment effects, as described in the exploratory endpoint of Part 2.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Comparative, single-cohort, interventional study model: investigational device vs. comparator device. Measurements are performed on the same cohort of participants: Part 1 - cross-sectional study; Part 2 - prospective study.
| Arm | Type | Receives |
|---|---|---|
| Fracture risk prediction in middle-aged and elderly men and women | Experimental | Device: Measurements with the POROUS R3C ultrasound device at the midshaft tibia, Device: DXA measurement of the hip and lumbar spine, Device: DXA-based Vertebral Fracture Assessment (VFA), Device: Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)All participants are examined with the investigational device (POROUS R3C ultrasound device) and a comparator device (DXA). |
Who may qualify
- Ages
- 56 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (48 listed)
- Female or male individuals aged 56 to and including 85 years.
- Written informed consent has been obtained.
- To avoid over- and under-recruiting with regard to the required sample size of participants with ≥ 2-fold increased age-and sex-adjusted risk for hip and vertebral fractures and participants with < 2-fold increased age- and sex-adjusted risk, clinical risk factors necessary for the calculation of the risk for hip and vertebral fractures (based on the risk calculation scheme outlined in the DVO osteoporosis guideline) are assessed at Screening.
- Vertebral fracture(s) during the last year
- Vertebral fracture(s) > 12 months ago
Key exclusion criteria (20 listed)
- Presence of diseases that rule out valid measurements with the DXA and/or POROUS R3C devices (e.g., fractures or metal implants in the examined bones, paralysis of the lower extremities, severe bone abnormalities).
- Inability to undergo the investigations required by the Clinical Investigation Plan (CIP) or cognitive limitations that preclude understanding of the Participant Information Sheet and the Informed Consent Document.
- Previous medical procedures involving exposure to a cumulative dose of ionising radiation deemed by the Investigator to exceed usual limits within standard of care.
- Pregnancy and breastfeeding
- Enrolment in any other interventional clinical study (current or during the last three months)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Measurements with the POROUS R3C ultrasound device at the midshaft tibiaThe POROUS R3C ultrasound device measures the cortical bone of the midshaft tibia. Ultrasound gel is first applied onto the skin surface, covering the region of interest, followed by placing the ultrasound transducer with a medical ultrasound gel pad placed in front of it. At the marked position on the leg, four technical measurement readings are performed: 2x CortBS and 2x Multifocus, with repositioning the probe between individual measurements, the chronological order of which is not crucial. Scanning time for each measurement takes 1-2 minutes. Out of the four measurements, the two optimal measurements (one for CortBS and one for Multifocus) are selected by the device, based on pre-defined quality criteria. | Device | Fracture risk prediction in middle-aged and elderly men and women |
| DXA measurement of the hip and lumbar spineThe following DXA measurements are to be performed: * Spine L1-4 * Hip left * Hip right (alternatively, if a valid measurement of the left hip is not possible) Scanning takes approximately 15 minutes. A maximum number of one repeat measurement is planned (e.g., hip or spine). Note: The DXA scan of the hip is performed on the same side of the body as the POROUS R3C ultrasound scan. | Device | Fracture risk prediction in middle-aged and elderly men and women |
| DXA-based Vertebral Fracture Assessment (VFA)DXA-based Vertebral Fracture Assessment (VFA) of thoracic and lumbar spine from T4 to L5. | Device | Fracture risk prediction in middle-aged and elderly men and women |
| Projectional radiography of thoracic spine (alternative to DXA-based VFA, if VFA is not available)Projectional radiography of thoracic spine T4-T12 and lumbar spine L1-L5. | Device | Fracture risk prediction in middle-aged and elderly men and women |
Primary outcome
Clinical Endpoint, Part 1 - POROUS-Score based on prevalent fractures
Time frame: 12 months
Prevalent fractures are the focus of the analysis in Part 1, i.e., fractures that occurred prior to the Baseline visit. This is reflected in establishing corrected standardized odds ratio (sOR) for the POROUS R3C ultrasound device-derived POROUS-Score. Statistically significant discriminative power of the sOR will be achieved if the lower limit of the 90% confidence interval of the sOR is greater than 1. The POROUS-Score will be evaluated to demonstrate the discriminative performance of the POROUS R3C ultrasound device for prevalent fractures. Outcome measure: POROUS-Score (units on scale)
Clinical Endpoint, Part 2 - POROUS-Score based on incident fractures
Time frame: 24 or 36 months
Incident fractures are the focus of the analysis in Part 2, i.e., fractures that occur after the Baseline visit until the EoS. This is reflected in establishing corrected standardized relative risk (sRR) for the POROUS R3C ultrasound device-derived POROUS-Score. Statistically significant prediction power of the sRR will be achieved if the lower limit of the 90% confidence interval of the sRR is greater than 1. The POROUS-Score will be evaluated to demonstrate the predictive performance of the POROUS R3C ultrasound device for incident fractures. Fractures, which are associated with cortical bone and/or increasing age, will be considered for collecting information on both prevalent and incident fractures. Any incident fractures caused by high-energy external forces will be excluded (censored) from the analysis. Outcome measure: POROUS-Score (units on scale)
5 secondary outcomes
Safety Endpoint
Time frame: 36 or 48 months
Performance Endpoint, Part 1 - DXA T-score
Time frame: Immediately after the intervention
Performance Endpoint, Part 1 - discriminative performance based on prevalent fractures
Time frame: 12 months
Performance Endpoint, Part 2 - DXA T-score
Time frame: Immediately after the intervention
Performance Endpoint, Part 2 - predictive performance based on incident fractures
Time frame: 24 or 36 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2026.
- Background: PubMed 34761144Armbrecht G, Nguyen Minh H, Massmann J, Raum K. Pore-Size Distribution and Frequency-Dependent Attenuation in Human Cortical Tibia Bone Discriminate Fragility Fractures in Postmenopausal Women With Low Bone Mineral Density. JBMR Plus. 2021 Sep 2;5(11):e10536. doi: 10.1002/jbm4.10536. eCollection 2021 Nov.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gabriele G Armbrecht, MD, PhD principal investigator
Zentrum für Muskel- und Knochenforschung
6 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Measurements with the POROUS R3C ultrasound device at the midshaft tibia, DXA measurement of the hip and lumbar spine and DXA-based Vertebral Fracture Assessment (VFA) in people with Healthy and Osteopenia, run by POROUS GmbH at 6 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 48 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in Germany, Austria, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical Endpoint, Part 1 - POROUS-Score based on prevalent fractures (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06567054, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2026.